CBDv

• Apr 06, 2021
• Category: Full-Spectrum Hemp Oil
• Source: Dinafem

https://www.dinafem.org/en/blog/what-is-cbdv/

• As the medical and scientific community becomes increasingly involved in research on the medical benefits of cannabis, new and promising cannabinoids such as CBDV come to light.
• Packed with health benefits, CVDB has been found to be a potent anticonvulsant with great potential in the medical field.
• Also, CBDV does not produce the psychoactive effect associated with cannabis use, which makes it particularly interesting for treating a variety of conditions.
• CBDV is not water soluble – at least not in significant amounts – and thus has poor bioavailability when administered orally (less than 6% in humans). Accordingly, alternative routes of administration are recommended.
• Recent studies have pointed to the great therapeutic potential of CBDV, prompting companies such as GW Pharmaceuticals to initiate research into the cannabinoid. According to the results so far, most of which obtained from animals, cannabidivarin may help treat epilepsy, autism and neuropathic pain.

CBDV and autism: While there is little research evaluating the effect of CBDV on autism, companies such as GW Pharma have already initiated studies to identify the medical applications of the cannabinoid for autism spectrum disorder. Based on the promising results so far, the coadministration of CBDV and CBD has the potential to improve cognitive and social skills, as well as to reduce compulsive and repetitive behaviours. Initiated last December and now on its second stage trials, one of these studies is exploring the safety of CBDV on autistic children, which are being treated with doses of 10mg/kg/day.

CBDV and Rett syndrome: Rett syndrome is a neurological disorder that occurs almost exclusively in girls and women. Caused by mutations on the X chromosome, it is characterised by the impairment of cognitive, sensory, emotional, motor and autonomic function (repetitive hand movements, slower brain growth and intellectual disability). A study on mice found that CBDV may contribute to reversing the deterioration and atrophy of the brain areas involved in Rett syndrome, and GW Pharma has already initiated research efforts aimed at proving the effectiveness of cannabidivarin in the treatment of the disease.

CBDV and neuropathic pain: While research is still limited, studies like this one initiated in 2015 are already examining the effects of CBDV on pain. The clinical trial stage, involving patients suffering from HIV-related chronic neuropathic pain, is still ongoing, and thus results are not yet available. There are indications, however, that the cannabinoid could be effective in reducing this type of pain, but further research is necessary to confirm the hypothesis.
CBDV and nausea: A common treatment option for nausea, cannabis is widely used to reduce the side effects of chemotherapy. In line with this, a study on mice found that both THCV and CBDV are effective antiemetics.

The link between CBDV and 2-AG

Despite the fact that it has taken scientists a while to decipher how CBDV is created, the cannabinoid has caught the eye of the pharmaceutical world. CBDV is unique because it does not prompt a reaction from either type of CB receptor. Instead, the secret to CBDV’s therapeutic potential comes from the way it can activate or desensitise our transient receptor potential channels (TRP channels).
The second prominent attribute of CBDV is its ability to affect the production of 2-arachidonoylglycerol (2-AG), one of our body’s endocannabinoids. It is also a characteristic that further separates it from the capabilities of CBD. By preventing the creation of the diacylglycerol lipase enzyme, the body is unable to synthesise 2-AG as it usually would. While the clinical implications of CBDV’s ability to inhibit 2-AG are not known, doing so does not prevent CBDV from carrying out its anti-epileptic duties.

What Is CBDV (Cannabidivarin) & What Does This Cannabinoid Do?

CBDV is also showing promise in several other areas of medicine:

• According to a 2018 rodent study, CBDV has shown promise in helping the neurobehavioral issues associated with Rett syndrome. Rett syndrome is caused by an X chromosome mutation that affects girls with seizures, speech issues, and muscle spasticity. Interestingly, CBDV seems to help with both the genetically determined and chemically-induced forms of this and similar diseases.
• In an animal study published in 2019 in the Journal of Psychopharmacology, CBDV was found to rescue memory defects in mice that have the same genetic defect as people with Rett syndrome. CBDV also helped with neurological defects, but the effects were transient.
• In a similar 2019 study published in the British Journal of Pharmacology, CBDV was found to possibly benefit patients with Duchenne muscular dystrophy (DMD). This disease is characterized by chronic inflammation and irreversible skeletal muscle damage and degeneration. CBDV may reduce inflammation and restore and even enhance muscle function. CBDV also improved locomotion, highlighting the compound’s potential as a novel therapy for DMD.
• Childhood intractable epilepsy and autism spectrum disorder (ASD) often go hand in hand. CBDV is being investigated as a potential treatment of some of the more significant ASD issues, such as repetitive behavioral problems, cognitive challenges, and communication and social functioning issues.
• CBDV may also be a powerful anti-nausea agent. Initial research on rodents shows that CBDV likely acts as an agonist to the CB1 receptors, thereby blocking the nausea response.

Although CBDV was discovered 50 years ago, research is just commencing in an appreciable way. With GW Pharmaceuticals and their CBDV clinical trials underway, this is a hopeful beginning in unlocking the secrets of another potentially powerful cannabinoid.